Response of Estrogen Receptor-Positive Breast Cancer Tumorspheres to
                    Antiestrogen Treatments by Ao, Ada et al.
Response of Estrogen Receptor-Positive Breast Cancer
Tumorspheres to Antiestrogen Treatments
Ada Ao
1*, Brian J. Morrison
2,3, Heiman Wang
1, J. Alejandro Lo ´pez
2,3, Brent A. Reynolds
4, Jianrong Lu
1*
1Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, Florida, United States of America, 2Queensland Institute of
Medical Research, Royal Brisbane Hospital, Brisbane, Australia, 3Griffith University, Nathan, Australia, 4Department of Neurosurgery, McKnight Brain Institute, University
of Florida, Gainesville, Florida, United States of America
Abstract
Estrogen signaling plays a critical role in the pathogenesis of breast cancer. Because the majority of breast carcinomas
express the estrogen receptor ERa, endocrine therapy that impedes estrogen-ER signaling reduces breast cancer mortality
and has become a mainstay of breast cancer treatment. However, patients remain at continued risk of relapse for many
years after endocrine treatment. It has been proposed that cancer recurrence may be attributed to cancer stem cells (CSCs)/
tumor-initiating cells (TICs). Previous studies in breast cancer have shown that such cells can be enriched and propagated in
vitro by culturing the cells in suspension as mammospheres/tumorspheres. Here we established tumorspheres from ERa-
positive human breast cancer cell line MCF7 and investigated their response to antiestrogens Tamoxifen and Fulvestrant.
The tumorsphere cells express lower levels of ERa and are more tumorigenic in xenograft assays than the parental cells.
Both 4-hydroxytamoxifen (4-OHT) and Fulvestrant attenuate tumorsphere cell proliferation, but only 4-OHT at high
concentrations interferes with sphere formation. However, treated tumorsphere cells retain the self-renewal capacity. Upon
withdrawal of antiestrogens, the treated cells resume tumorsphere formation and their tumorigenic potential remains
undamaged. Depletion of ERa shows that ERa is dispensable for tumorsphere formation and xenograft tumor growth in
mice. Surprisingly, ERa-depleted tumorspheres display heightened sensitivity to 4-OHT and their sphere-forming capacity is
diminished after the drug is removed. These results imply that 4-OHT may inhibit cellular targets besides ERa that are
essential for tumorsphere growth, and provide a potential strategy to sensitize tumorspheres to endocrine treatment.
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Introduction
The steroid hormone estrogen is central to the etiology of breast
cancer. The biologic effects of estrogen are primarily mediated by
estrogen receptors, namely ERa and ERb [1]. In classic estrogen
signaling, the binding of estrogen to ER causes receptor
dimerization and binding to estrogen response elements (EREs)
in promoter and/or enhancer regions of estrogen-responsive
genes. Estrogen binding alters the three-dimensional structure of
ER to facilitate recruitment of coactivator complexes, thereby
activating the transcription of estrogen-inducible genes. The
resultant transcriptional changes promote cell proliferation,
survival, angiogenesis, and tumor metastasis.
ERa is a key transcriptional regulator in breast cancer and is
responsible for many of the effects of estrogen on cancerous breast
tissue. The majority of breast cancers are ERa-positive and
depend on estrogen for growth [2]. Therefore, endocrine therapy
that interferes with estrogen-mediated actions has been the
strategy of choice for the treatment and prevention of ER-positive
breast cancer. Clinically, inhibition of the estrogen signaling
pathway is achieved mainly by targeting ER with selective ER
modulators (SERMs) or the pure antiestrogen Fulvestrant, and
blocking estrogen synthesis through aromatase inhibition [3], [4].
SERMs are synthetic molecules which bind to ER and
modulate its transcriptional activity to block estrogen-stimulated
breast cancer growth. Tamoxifen, the prototypical SERM, is the
first-line therapy and a current standard adjuvant treatment
extensively used for all stages of ER-positive breast cancer. 4-
hydroxytamoxifen (4-OHT), the active metabolite of Tamoxifen,
binds to ER in the same pocket as estrogen, but confers a
conformation to the complex that is distinct from estrogen-bound
ER. Consequently, binding of 4-OHT not only blocks association
of coactivators but also recruits corepressors to prevent
transcription of estrogen responsive genes [5]. Adjuvant therapy
with 5 years of Tamoxifen reduces the disease recurrence rate by
half and the annual breast cancer mortality rate by one-third,
contributing significantly to the reduced mortality of estrogen-
sensitive breast cancer [6]. Tamoxifen is also effective in
prevention of breast cancer, decreasing its incidence by
approximately 50% [7]. Fulvestrant/ICI182780 (ICI) has been
approved as a second-line endocrine therapy for ER-positive
breast cancer. ICI has a unique mode of action. It competitively
binds to ER with high affinity and induces a conformational
rearrangement that leads to accelerated degradation of ER
protein [8]. ICI has shown equivalent clinical efficacy compared
to Tamoxifen.
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survival in patients with ER-positive breast cancer. It has evolved
to become the most effective and least toxic systemic therapy for
this form of breast cancer. However, breast cancer recurrence
after antiestrogen therapy has been a significant barrier for long-
term positive outcome. Although Tamoxifen lowers the risk of
recurrence for several years, late recurrences remain a major
clinical challenge. Among women treated with a recommended 5-
year Tamoxifen regimen, one-third of them would experience
recurrent disease within 15 years [6].
There is increasing evidence that tumor persistence and
recurrence may be attributed to cancer stem cells (CSCs) [9],
[10], [11]. According to the CSC model, tumors are heteroge-
neous and many of them are organized as hierarchies in which a
subpopulation of cancer cells, proposed as CSCs or tumor-
initiating cells (TICs), possess stem cell-like properties. These cells
can self renew as well as produce progenitors that rapidly
proliferate and subsequently differentiate into diverse, more
mature cell types that form the bulk of a tumor. TICs are
intrinsically resistant to conventional chemo- and radiation
therapies, and are able to regenerate the cellular components of
the original tumor eradicated by such treatments, leading to
recurrence. How to target and eliminate TICs is key to the design
of more effective therapies.
It therefore becomes a critically important question how TICs
from ER-positive breast cancer respond to endocrine therapy.
Because bona fide markers for TICs are elusive, the exact identity of
TICs remains contentious. Several complementary approaches
have been used to enrich breast cancer TICs. The formation of
mammospheres/tumorspheres in suspension culture is thought to
be a hallmark of TICs [12], [13]. Serial passaging of spheres is an
accepted measurement of self-renewal. Breast tumorspheres have
been established from primary tumors and established cell lines.
Breast cancer-derived sphere cells exhibit higher resistance to
radiation and chemotherapy [14], [15], [16], and greater
tumorigenic potential [17], [18]. However, it has not been reported
whether these cells are responsive to anti-hormonal treatment.
The aim of this study was to characterize putative TICs from
ER-positive breast cancer for their response to endocrine
treatment in order to better understand and ultimately reduce
tumor recurrence. In the present study, tumorspheres were
established from ER-positive breast cancer cell line MCF7 and
subjected to 4-OHT and ICI treatments. These treatments
attenuated tumorsphere growth. However, after the treatments
were stopped, the sphere formation frequency and tumorigenic
potential of these cells remained unchanged. We further
investigated the role of ERa in sphere growth and response to
antiestrogens, and found that depletion of ERa unexpectedly
sensitized tumorsphere cells to 4-OHT treatment.
Results
Tumorspheres derived from the MCF7 breast cancer cells
exhibit increased tumor-initiating potential
The human breast cancer cell line MCF7 has been frequently
used to isolate TICs, which grow as non-adherent tumorspheres
[13], [14]. MCF7 cells were cultured under suspension conditions
at 5,000 cells per ml in tumorsphere media [12], and they formed
increasingly larger spheroids (Figure 1A). Eight days after initial
plating, the cells formed tightly-packed, multicellular spheroids
typically over 50 microns in diameter (Figure 1A).
Based on changes in cell proliferation kinetics (Figures 1B), the
selection process appeared to be complete after the third passage
(or the formation of tertiary spheroids). Cell proliferation rate
became stabilized at approximately 200-fold change from passage
3 onward. These MCF7-derived tumorsphere cells were referred
to as MCF7S.
CD44 was previously described as a putative tumorigenic
marker in breast cancer [19], and tumorsphere-forming cells
were frequently enriched by isolating the CD44
high/CD24
low
cell population [16], [18], [20], [21], although the properties of
the cell subgroup expressing CD44 and its specific role in
tumor-initiation remain controversial. The status of CD44 in
MCF7S and MCF7 parental cells was determined. Approxi-
mately 60% of MCF7S cells expressed the CD44 antigen while
less than 2% of MCF7 parental cells expressed the marker
(Figure 2A), suggesting that tumorsphere culture robustly
enriched CD44-positive cells. Another marker, CD24, appeared
Figure 1. Establishment of tumorspheres from MCF7. A. Phase contrast images of tumorspheres derived from MCF7 cells 2, 4, and 8 days after
initial seeding. Red arrows (bottom left) indicate microspikes, which are presumed to be microfilaments that spheroid cells use to sense nutrients in
the environment. Hoechst nuclei staining (bottom right) shows a multicellular tumorsphere. Magnification at 100x. Scale bar =100 microns. B.
Growth kinetics of MCF7S. Cells were seeded at 10,000 per ml and allowed to grow for seven days. The cells were then dissociated, counted, and
passaged on the seventh day. This was repeated for 6 weeks. The experiment was performed twice with technical triplicates each time. Fold change is
shown as final cell density/initial cell density.
doi:10.1371/journal.pone.0018810.g001
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population of MCF7 adherent cells (Figure S1). This discrep-
ancy could be due to the heterogeneous nature of spheres,
which contain differentiated cell types and variable proportions
of TICs.
MCF7-derived tumorsphere cells were reported to be more
tumorigenic than the parental cells [17]. The tumor forming
potential of MCF7S cells was evaluated using in vivo tumorigenic
assay. As shown in Figure 2B, tumors derived from MCF7S cells
were significantly larger than those from parental MCF7
beginning 16 days post-injection, which continued to increase
over time (e.g. Day 16 p=0.011, Day 23 p=0.041, Day 30
p=0.005, Day 37 p=0.005). MCF7S cells formed tumors more
efficiently and had greater in vivo growth potential than the
parental MCF7. These data suggest that the tumorsphere culture
selects cells with tumorigenic potential.
MCF7S cells retain ERa expression
Previous studies have argued that tumorsphere formation is
associated with ERa-negative, basal cell types [22], [23]. More
recent evidence suggests that a stem cell hierarchy exists during
mammary stem cell development that supports the notion of a
lineage-restricted, ERa-positive progenitor cell [24]. ERa-positive
breast stem cells have been reported [25]. The parental MCF7
cells are positive for ERa, but it is unclear if ERa expression is
altered during tumorsphere formation.
With these conflicting viewpoints, ERa expression in MCF7S
cells was examined and compared to parental MCF7 cells.
Immunoblotting with anti-ERa antibodies detected the presence
of ERa protein in MCF7S cells, but its level was modestly
downregulated as compared to MCF7 monolayer cells (Figure 3A).
Indirect immunofluorescence assay was used to determine ERa
protein expression at the single cell level (Figure 3B). ERa was
Figure 2. Increased tumorigenecity of MCF7S cells. A. Histogram of CD44-FITC and Iso-FITC staining for MCF7P and MCF7S. Duplicates are
shown. Percentages of CD44 positive staining (from 30,000 cells) are indicated. Representative scatter plot and gating of FACS sorted cells is shown as
inset. B. In vivo tumorigenic assay for MCF7 parental and MCF7S tumorsphere cells. Five mice were used for each group.
doi:10.1371/journal.pone.0018810.g002
Figure 3. Estrogen receptor status in MCF7S. A. Immunoblotting of ERa protein in MCF7P and MCF7S cells. Tubulin served as loading control.
B. Indirect immunofluorescence for ERa protein (green) in MCF7P and MCF7S. Cells were fixed by 3.7% formaldehyde. HOECHST 33342 (blue) was
used to indicate nuclear region. A negative control was performed without primary anti-ERa antibody. Magnification at 40x.
doi:10.1371/journal.pone.0018810.g003
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MCF7S. Examination of hundreds of individual MCF7S cells
showed that they were all positive for ERa (Figure 3B).
Because of their ERa positivity, we investigated the effect of
antiestrogens on the abundance and subcellular localization of
ERa in MCF7S cells. Cell fractionation analysis was performed for
both parental MCF7 and MCF7S cells after antiestrogen
treatment for 48 hours. ERa protein was detected in MCF7S
cells (Figure 4A). As expected, ICI downregulated overall ERa
protein levels in both MCF7S and MCF7 parental cells. By
contrast, 4-OHT strongly increased ERa protein in the nuclear
fraction (Figure 4A and B), which is consistent with previous
reports that 4-OHT stabilizes ERa in the nucleus [26], [27].
Antiestrogens 4-OHT and ICI differentially attenuate
tumorsphere formation and proliferation
We next queried whether and how antiestrogen treatments
might affect tumorsphere cells. MCF7S cells were treated with
vehicle alone or singly with various concentrations of 4-OHT and
ICI at the time of seeding. The cells were incubated for 6 days and
tumorspheres were scored. As shown in Figure 5, treatment with
4-OHT at 2.5 mMo r5mM remarkably disrupted tumorsphere
formation and caused the cells to form disordered aggregates.
However, cells exposed to vehicle controls, 1 mM 4-OHT, 0.5 and
1 mM ICI, still formed normal-looking spheroids. Therefore, the
two classes of antiestrogens, 4-OHT and ICI, displayed different
effects on sphere formation.
We further determined whether antiestrogens might influence
MCF7S cell proliferation. The cells were treated with antiestro-
gens on the day of seeding. The cells were then counted 2 days, 4
days, or 6 days after seeding to determine the proliferation rate of
these cells in the presence of antiestrogens. MCF7S responded to
antiestrogens in a dose-dependent manner (Figure 6A). Prolifer-
ation of MCF7S cells were not significantly affected by 1 mM4 -
OHT, while 2.5 mM 4-OHT significantly decreased cell prolifer-
ation by about 50% (p,0.05). MCF7S proliferation was essentially
stopped by 5 mM 4-OHT. The effects of 1 mM ICI treatment were
comparable to that of 2.5 mM 4-OHT for the inhibition of
MCF7S proliferation (Figure 6A). MCF7S cells treated with
0.5 mM ICI showed a decrease in cell proliferation, although it was
not significant when compared to 0.1% DMSO control
(Figure 6A). Therefore, both antiestrogens at higher concentra-
tions were capable of attenuating MCF7S proliferation.
MCF7S sphere-forming and tumorigenic potential is
unaffected after short term antiestrogen treatment
An interesting question was whether antiestrogen treatments
might affect tumorsphere-forming potential. Therefore, MCF7S
cells pre-treated with antiestrogens for various days were replated
in media without drugs and sphere formation frequency was
quantified. Approximately 5%–10% of bulk MCF7S cells were
capable of sphere formation (Figure 6B). There was no statistically
significant decrease in sphere formation efficiency following ICI
treatment with the exception of 2 days 0.5 mM ICI treatment
(p=0.028). Sphere formation ceased in the presence of 4-OHT
(2.5 mM or higher), but resumed when the drug was removed.
There was a statistically significant increase in sphere forming
frequency with 1 mM (p=0.0004, 2 days) and 2.5 mM 4-OHT
(p=0.014, 2 days; p=0.021, 6 days) treatments (Figure 6B). These
results implied that sphere formation frequency of MCF7S cells
remained essentially stable following ICI treatment, and 4-OHT
might select for cells with mildly increased sphere-forming
potential.
Tumorsphere formation correlates with enrichment of tumor-
initiating cells and may serve as an indicator of tumor-forming
potential [15], [18]. In vivo tumorigenic assay was performed in
Figure 4. Effects of antiestrogens on ERa abundance and subcellular localization. Immunoblot of ERa protein in cytoplasmic and nuclear
fractions from MCF7S (A) or MCF7 parental cells (B) treated for 48 hours with 4-OHT or ICI. Densitometry quantification of three independent
experiments is shown below. Tubulin was used as a loading control for cytoplasmic (C) and LSD1 for nuclear (N) fraction. Statistically analysis was
performed using paired Student’s t-test.
doi:10.1371/journal.pone.0018810.g004
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MCF7S cells following antiestrogen challenge. MCF7S cells were
pre-treated for 4 days, recovered in fresh media for 6 days, and
subjected to xenograft transplantation. The resulting tumors
showed no significant differences in tumor size when compared to
untreated control (Figure 6C), implying that antiestrogen
treatments did not alter the tumorigenic potential of MCF7S
cells.
MCF7S cells retain self-renewal capacity in long-term
antiestrogen treatment
According to the CSC/TIC hypothesis, self-renewing TICs
only grow and divide asymmetrically to maintain homeostasis,
and the growth of the bulk population is dependent on non-
tumorigenic cells. If MCF7S does indeed contain a subpopula-
tion of TICs, then it is possible to examine this property through
long-term serial passage. This method, which has been used in
neural stem cells characterization [28], can characterize the
effects of antiestrogens on long-term self-renewal of tumorigenic
cells.
This was achieved by serially passaging viable cells for multiple
passages. The cells were treated either with vehicle alone or
antiestrogens at the time of seeding, and incubated for 7 days as
constituting a single passage. Viable cells were counted at the end
of each passage. The fold change in cell number for each passage
was used to calculate potential expansion of the population if all
the cells, instead of a fraction, were maintained in culture. The
long term growth kinetics was compared between different
antiestrogen treatments.
Control treatment (0.1% DMSO) did not influence long term
cell expansion of MCF7S (Figure 7A). There was a decrease in
long term expansion for 1 mM and 2.5 mM 4-OHT treated
MCF7S, and 5 mM 4-OHT and ICI treated cells showed the
most dramatic decrease in long term expansion (Figure 7A). It is
evident that all antiestrogen treatments reduced MCF7S
long term growth. The results indicated that decrease in long-
term cell expansion did not correlate with sphere formation
frequency.
Cell cycle analysis with propidium iodide staining further
confirmed the changes in growth rate. Cells treated with 4-OHT
Figure 5. Effects of antiestrogens on tumorsphere formation. (Top) Phase-contrast images of MCF7S cells in the presence of antiestrogens or
vehicle controls for 7 days. (Bottom) Quantification of MCF7S spheres with .50 micron diameter. Magnification at 1006. Scale bar =100 microns.
doi:10.1371/journal.pone.0018810.g005
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significantreduction of S phase cell population when compared
to vehicle-treated control cells (Figure 7B). These results
suggested that antiestrogen treatments attenuated cell cycle
progression, which might contribute to the decrease in long-term
expansion.
Figure 6. MCF7S antiestrogen response in vitro.A . Cell proliferation of MCF7S in the presence of antiestrogens. Cell proliferation of MCF7S
treated with 4-OHT (top) or ICI (bottom) from four independent experiments. Error bars represent standard error of the mean (S.E.M.). B. Sphere
formation of MCF7S after antiestrogen challenge with 4-OHT or ICI. (Top) Sphere formation frequency of 4-OHT-(top) or ICI-(bottom) treated MCF7S
from four independent experiments. Plating efficiency was calculated as number of sphere .50 microns in diameter/total number of cells seeded
6100%. Error bars represent S.E.M. C. In vivo tumorigenic assay for MCF7S cells following antiestrogen challenge. MCF7S were either untreated,
treated with 2.5 mM 4-OHT or 1 mM ICI for 4 days then recovered for 6 days in culture without antiestrogens, prior to injections. At least 4 mice were
injected for each condition.
doi:10.1371/journal.pone.0018810.g006
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potential in vivo
ERa is the primary target of antiestrogens. The evidence that
tumorsphere formation persisted in the presence of ICI suggested
that ERa might not be essential for sphere formation, although it
could influence cell proliferation in bulk tumorsphere culture.
Therefore, it was necessary to examine ERa’s role in the context of
potential TICs.
ERa was specifically depleted using shRNA via retroviral
transduction. Three stable knockdown (shER) clones with efficient
depletion of ERa were identified (Figure 8A). Compared to bulk
MCF7S cells, clone 11 exhibited much lower proliferation rate,
but clones 7 and 9 did not show significant reduction in growth
(Figure 8B). All three shER clones were capable of forming spheres
at sizes and frequencies similar to those of control MCF7S cells
(not shown), confirming that ERa was not required for tumor-
sphere formation or maintenance.
We further determined whether ERa was required for the
tumorigenic potential of MCF7S cells. In vivo tumorigenic assay
was performed to compare retroviral-mediated ERa knockdown
cells to control shRNA-transduced cells. There was no statistically
significant difference in tumor volume between control shRNA
transduced MCF7S and shER MCF7S cells (Figure 8C). In
addition, following antiestrogen pre-treatment, both control
shRNA and shER transduced MCF7S cells showed no statistical
differences in tumor growth (Figure 8D and E), which is analogous
to data from bulk MCF7S (Figure 6C). In conclusion, these
observations suggest that ERa is dispensable for sphere formation
and tumorigenicity of MCF7S.
Depletion of ERa sensitizes MCF7S cells to 4-OHT
treatment
The indication that ERa is not required for sphere formation
raised questions about its role in MCF7S’ antiestrogen response.
The ERa knockdown clones were further characterized for
proliferation and sphere formation frequency under antiestrogen
treatment. All three clones exhibited similar responses. Unlike the
control shRNA MCF7S cells, the shERa clones demonstrated
diminished response to ICI, as the compound had no significant
effect on cell number (Figure 9A). This indicates that ERa has
been sufficiently depleted in the shERa cells to nullify ICI’s effects
and that ICI’s activity depends on the presence of ERa.
Unexpectedly, the shERa cells exhibited a much heightened
sensitivity to 4-OHT treatment (Figure 9A).
The sphere formation capacity of the shERa clones was
evaluated as described for Figure 6b. The ERa knockdown clones
pretreated with vehicle or ICI for 6 days showed similar sphere
formation frequency to that of control shRNA MCF7S
(Figure 9B). However, a dramatic reduction in sphere formation
potential was observed in shERa cells treated with 4-OHT
(Figure 9B). Because sphere formation is a measurement of TIC
self-renewal capacity, this finding implies that 4-OHT treatment
may be able to shrink the pool of TICs in MCF7S cells depleted
of ERa.
Figure 7. Effects of antiestrogens on long-term growth and cell cycle of MCF7S. A. Long-term expansion of MCF7S in the presence of
antiestrogens. The lines are expressed on a semilog graph (top) and slope of each line was calculated as log of averaged expansion (bottom). Data
were derived from four independent experiments. Error bars: S.E.M. B. Propidium iodide (PI) cell cycle analysis of 48 (top) and 72 (bottom) hours
antiestrogen treated MCF7S. Data were derived from four independent experiments and analyzed using ModFit LT software. Error bars: S.E.M.
doi:10.1371/journal.pone.0018810.g007
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Adjuvant endocrine therapy of ER-positive breast tumors is an
important advance in breast cancer treatment. These hormonal
interventions reduce the disease recurrence rate, however, many
patients treated with the therapies still suffer relapse years later. A
better understanding of the mechanisms underlying tumor
recurrence should improve therapeutic efficacy and reduce
mortality from ER-positive breast cancer. The concept of cancer
stem cells responsible for tumor recurrence has increasingly gained
prominence in breast cancer research. This model suggests that
only a minority population of cells in tumors, termed CSCs/TICs,
possess extensive self-renewal potential and are able to sustain
tumor growth, metastasis, and recurrence [9], [10], [11]. To
eliminate residual breast cancer disease after endocrine therapy
may require effective targeting of this cell population. The CSC/
TIC theory has profound implications for our understanding of
tumor recurrence and for the design of novel treatments.
However, how the TICs from ER-positive breast tumors react to
antiestrogen treatment were unclear.
The TICs are recognized by their capacity to grow as
tumorspheres in vitro and initiate tumor formation in vivo [12],
[13], [19]. In this study, tumorspheres derived from the ERa-
positive MCF7 breast cancer cell line were used as a model to
characterize their response to antiestrogen treatment. Tumor-
sphere cells demonstrated increased tumorigenicity when trans-
Figure 8. ERa is disposable in MCF7S. A. Immunoblot analysis of ERa in three shERa MCF7S clones. Relative densitometry intensity is shown. B.
Cell proliferation of three shERa clones compared to bulk MCF7S culture. Error bars represent standard deviation from two experiments. C. In vivo
tumorigenic assay comparing shRNA control and shERa knockdown MCF7S. Five mice were injected for each condition. D and E. In vivo tumorigenic
assay comparing antiestrogen treated (4 days) shRNA control or shERa MCF7S cells. At least 4 mice were injected for each condition.
doi:10.1371/journal.pone.0018810.g008
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cells. The sphere cells retained ERa expression (albeit at reduced
levels when compared to parental cells) and were responsive to
antiestrogens. Acute antiestrogen treatment with 4-OHT or ICI
decreased their proliferation. However, the treated cells retained
the same capability of sphere formation in vitro and tumorigenicity
in vivo. After withdrawal of the drugs, tumorsphere growth
resumed. The comeback tumorsphere cells remained sensitive to
antiestrogens as repeated, longer-term antiestrogen treatment
inhibited cell expansion. There was no indication of strong
enrichment of antiestrogen resistant cells. This is consistent with
previous findings that antiestrogen-resistant clones are rare and
require remarkably prolonged selective pressure in vitro to isolate
[29]. It should be pointed out that the concentrations of
Tamoxifen in breast tumors from patients under endocrine
therapy are mostly at 300–400 ng/g [30], or approximately
1 mM, which is slightly lower than that was used in this study. The
requirement of higher levels of Tamoxifen could be attributed to
the source of cells. Ideally, tumorspheres directly derived from ER-
positive clinical tumor samples will be examined for their
sensitivity to antiestrogen treatment. Consistent with our in vitro
observation, recent clinical studies demonstrate the positive impact
of extended endocrine therapy on suppressing late recurrences in
ER-positive breast cancer [31], [32].
Our study suggested that ERa was not essential for tumorsphere
formation or tumor growth, implying that TICs do not rely on
ERa for self-renewal (even though they may express detectable
levels of ERa). Surprisingly, ERa-depleted tumorspheres are
hypersensitive to 4-OHT treatment. It is likely that 4-OHT has
additional target(s) (other than ERa) in these cells that also
contribute to tumorsphere formation. Such target(s) may be
preferentially co-expressed with ERa, but their identity remains
unknown. Nevertheless, this observation that depletion of ERa
sensitizes tumorspheres to 4-OHT may be explored to target
TICs. On the other hand, this result does not indicate that
Tamoxifen is more effective on ER-negative tumors. It is widely
appreciated that ER-positive breast cancers have fundamentally
distinct clinicopathologic and genetic characteristics when com-
pared to ER-negative cancers [6], [33], [34], [35]. The benefit of
Tamoxifen is so far limited to the group of women with ER-
positive tumors. Simple depletion of ERa does not change other
properties of ER-positive tumor cells and make them equivalent to
ER-negative tumors.
Tumorsphere formation only enriches TICs, and the enrich-
ment of TICs may be variable. In a given sphere, only 5–10% of
the population possesses the self-renewal capacity to form new
spheres when plated (Figure 6B). If these cells represent TICs,
the majority of the bulk sphere cells are more differentiated cells
[12]. The heterogeneity in MCF7S seems to be rigidly
maintained, as the proportion of self-renewing cells remains
almost constant over multiple passages and after antiestrogen
treatment (Figure 6B). This homeostasis may suggest that non-
TIC cells may form a niche to support the maintenance of TICs.
The exact ERa status in different cell subpopulations in spheres
remains to be determined. TICs may express sufficient levels of
ERa and are direct targets of antiestrogens. It is also possible
that TICs only express minimal amount of ERa and are hence
intrinsically insensitive to antiestrogens. In this case, antiestro-
gens may target non-TIC cells in spheres and disrupt the niche
for TICs.
Figure 9. Antiestrogen response of ERa knockdown MCF7S cells. A. In vitro antiestrogen response of ERa knockdown in MCF7S cells.
% Relative Cell Number represents viable cell number in antiestrogen-treated samples relative to vehicle-treated control. Data for two individual
clones were generated from three independent experiments. Error bars represent S.E.M. B. Sphere formation frequency of antiestrogen treated ERa
knockdown MCF7S cells. Three independent experiments were performed for two individual clones. Error bars: S.E.M.
doi:10.1371/journal.pone.0018810.g009
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Antiestrogens, antibodies and shRNA constructs
4-Hydroxytamoxifen and ICI 182780 were purchased from
Sigma. Anti-ERa antibody for immunoblotting was purchased
from Santa Cruz (clone HC-20, SC543), and clone MC-20,
SC542 was used for immunofluorescence. CD44-FITC (clone
G44-26, 555478, BD Pharmingen) and Iso-FITC (MG2b01,
Molecular Probes) were kind gifts from Drs. Johannes W. Vieweg
and Sergei Kusmartsev.
Oligos for shRNA constructs were designed using psm2
designer at RNAi Central (http://katahdin.cshl.edu/siRNA/
RNAi.cgi?type=shRNA). The shRNA oligos were cloned into
the retroviral pLMP vector (OpenBiosystems).
Tumorsphere generation and formation assay
Tumorsphere media was composed of 50:50 DMEM/F12
media supplemented with 20 ng/ml EGF, 10 ng/ml bFGF, 5 mg
per ml heparin, 1% penicillin-streptomycin solution, 1% L-
glutamine, and 1X B-27 supplement [12]. MCF7 parental cells
from ATCC were seeded at 5,000 living cells per ml in defined
tumorsphere media onto Poly-HEMA coated dishes [12]. The
cells were passaged once a week to select for tumorsphere culture
cells. The culture was maintained without additional growth factor
supplementation or culture media change over the course of a
week from initial plating until the next passage for secondary
spheroids.
MCF7 tumorsphere single cell suspension was diluted to 5,000
cells per ml and plated onto 96-well plate (approximate 500 cells
per well). The cells were incubated for 6 days and phase contrast
pictures were taken. Sphere size and number were manually
measured and counted from the images using ImageJ software.
Statistical analysis was performed using Student’s t-test.
Expression of CD44 and CD24 by flow cytometry
Approximated 1610
6 cells were trypsinized to obtain single cell
suspension. The cells were washed twice in cold PBS + 1% BSA,
and subsequently incubated at 4 ˚C with either 1:25 diluted CD44-
FITC antibody, CD24-FITC antibody, or isotype-FITC control
antibody in PBS + 1% BSA for 45 minutes in the dark. After
incubation, the cells were washed twice in cold PBS + 1% BSA
and resuspended in 400 ml cold PBS + 1% BSA for flow cytometry
analysis within 1 hour.
In vivo tumorigenesis
All mouse work was conducted according to relevant national
and international guidelines. The Queensland Institute of Medical
Research Animal Ethics Committee (QIMR-AEC) approved this
project under protocol number P1159. 7–9 week old NOD.Cg-
Rag1
tm1MomIl2rg
tm1Wjl/SzJ mice (The Jackson Laboratory, Bar
Harbor, Maine) were used for the subcutaneous (s.c.) injections
of breast cancer cells. One day before transplantation, the mice
received 60-day release 17b-estradiol pellets (Innovative Research
of America, Sarasota, Florida) placed s.c. in the interscapular
region. Mice received 2610
6 cells mixed 1:1 in PBS and matrigel
(BD). Mice were monitored twice a week for overall health. Tumor
diameters were measured with a digital caliper and tumor volume
in mm
3 was calculated using the formula: Volume = width
2 6
length 60.5. The results were compared using unpaired t-test.
Supporting Information
Figure S1 CD24 expression in MCF7P and MCF7S cells.
Histogram of CD24-FITC and Iso-FITC staining for MCF7P and
MCF7S. Duplicates are shown. 10,000 cells were examined for
each staining.
(TIF)
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